Abstract 2370P
Background
Pembrolizumab (pembro) is approved for the II-line in mUC. In PEANUT trial (NCT03464734) we investigated the efficacy of the combination of pembro plus nab-paclitaxel after chemotherapy (CT) failure. Herein, a long-term follow-up (FUP) update and a post-hoc analysis are presented.
Methods
In an open-label, single-arm, phase 2 trial pts with mUC after failure of ≤2 platinum-based CT were enrolled. Pts received 200 mg pembro on D1, and 125 mg/m2 nab-paclitaxel on D1 and D8, every 3 weeks, until disease progression (PD) or unacceptable toxicity. The primary endpoint was the progression-free survival (PFS).
Results
As of April 1, 2023, 11/70 (15.7%) pts enrolled are in CR after a median FUP of 45.5 mo (95% CI, 42.3 – 49.8). 5/70 (7.1%) completed 2-yrs of treatment. Median OS was 11.7 mo (95% CI, 8.27 – 17.2) and median PFS was 5.1 mo (95% CI, 4.1 – 7.37). The ORR was 47.1%. For CR or PR pts, median OS was 28.4 mo (95% CI, 16.2 – NA). OS rate was 19 (27.1%) at 46 mo. Treatment was discontinued due to toxicity in 12/70 (17.4%) pts: in 9/70 only nab-paclitaxel, in 3/70 both. After PD, 22/70 (32.4%) patients underwent further therapies. Levels of hemoglobin (HR 0.88; 95% CI, 0.76 – 1; p value 0.095) and NLR at baseline (HR 1.2; 95% CI, 1.1 – 1.3; p value 0.0032), discontinuation due to toxicity (HR 0.34; 95% CI, 0.14 – 0.79; p value 0.012) and subsequent therapy (HR 2.4; 95% CI, 1.3 – 4.4; p value 0.0033) appear to have a statistically significant impact in PFS. Instead, the primary (bladder vs UTUC) (HR 2.3; 95% CI, 1.1 – 4.7; p value 0.027), liver metastases (HR 2.4; 95% CI, 1.3 – 4.2; p value 0.0032), NLR at baseline (HR 1.2; 95% CI, 1.1 – 1.3; p value 0.0014) and discontinuation due to toxicity (HR 0.38; 95% CI, 0.16 – 0.89; p value 0.026) seem to have a greater influence on OS.
Conclusions
After nearly 4 years, the combination of pembrolizumab and nab-paclitaxel maintained clinically meaningful efficacy in pts with mUC that progressed after platinum-based CT. OS data and post-hoc analyzes are consistent with what has been published in the literature in this disease setting.
Clinical trial identification
NCT03464734.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori di Milano - Italy.
Funding
This study was partially supported by Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Verzoni: Financial Interests, Personal, Principal Investigator: Janssen, Ipsen, MSD, Pfizer, Merck, Novartis. G. Procopio: Financial Interests, Personal, Advisory Board, consultant fees: Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, Novartis, Pfizer; Financial Interests, Institutional, Research Grant, research funding for no profit clinical trial: Ipsen. A. Necchi: Financial Interests, Institutional, Research Grant: Merck, AstraZeneca, Ipsen, BMS, Gilead; Financial Interests, Personal, Steering Committee Member: Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck, Clovis Oncology; Financial Interests, Coordinating PI: Incyte; Financial Interests, Local PI: Pfizer; Non-Financial Interests, Leadership Role: Global society of Rare Genitourinary Tumors (GSRGT). P. Giannatempo: Financial Interests, Personal, Local PI: Merck, Janssen; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Funding: Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23